In this review we will retrace the development of molecular-target drugs and the current therapeutic scenario for patients with BRAF mutated melanoma, from the introduction of BRAF inhibitors as single agents in 2011 to modern clinical practice. The gene discussed is BRAF; the disease is melanoma.